ALMS

AI Memo

Alumis

As of 2026-09-25/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-25 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Plaque-psoriasis NDA submission • 2026-12-31

Base target: $8 / p=50% prob

Biggest risk

The SLE setback may limit the value of a second indication; subgroup findings may not replicate or support registration. Psoriasis filing, review and eventual commercialization each carry separate execution risk. June 30 cash and marketable securities were $502.3 million, while quarterly R&D expense was $85.3 million, making spending and runway important to monitor [#PR-EARNINGS-2026-09-01] [#SEC-8K-2026-08-13].

Invalidation

Break below $4 or thesis failure.

What would change my mind?

A timely psoriasis NDA, supported by the reported ONWARD3 long-term response data, could restore confidence. A regulator-supported SLE trial design would add optionality, but the failed overall LUMUS result remains the controlling clinical fact [#SEC-8K-2026-08-13] [#PR-EARNINGS-2026-09-01].

Research note

Recommendation

—

Confidence

medium

As of

2026-09-25

Base target

p=50%

Bull target

$12

p=25%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

A-005 Parkinson’s biomarker trial initiation
Regulatory path for biomarker-defined SLE development
A timely psoriasis NDA, supported by the reported ONWARD3 long-term response data, could restore confidence.

BearKey bullets

Clinical development and potential launch preparation could increase cash needs; the $502.3 million cash and marketable-securities figure is dated June 30, 2026 [#SEC-8K-2026-08-13].
LUMUS missed its primary and secondary endpoints in the overall SLE population; a prespecified subgroup response does not reverse that result [#PR-EARNINGS-2026-09-01].
Low coverage and unavailable verified current analyst-target revisions limit valuation confidence.

WatchKey bullets

Plaque-psoriasis NDA submission

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $8 (p=50%)

Target spread vs base: +50% / -50%

Scenario probabilities

Bull Target: $12 (p=25%)Base Target: $8 (p=50%)Bear Target: $4 (p=25%)

Commentary

September 1 coverage reported a roughly 57%–58% selloff after the LUMUS result; the September 24 packet anchor of $7.29 is also below the prior baseline’s $7.94 reference. Director Form 4 activity included both purchases and sales, which is not evidence of operating progress [#SEC-FORM4-2026-09-09]. Verified current analyst revisions, options, short-interest, employee and social readings were not supplied; zeros in those numeric fields mean unavailable, not neutral.

As of 2026-09-25 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

A-005 Parkinson’s biomarker trial initiation
Regulatory path for biomarker-defined SLE development

Scenarios

Bull Target (Scenario probability)

$12 / p=25% prob

Base Target (Scenario probability)

$8 / p=50% prob

Bear Target (Scenario probability)

$4 / p=25% prob

Analysis 2026-09-25 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

-0.70

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
Plaque-psoriasis NDA submission
Alumis says it remains on track to submit an envudeucitinib NDA in Q4 2026. The submission is the clearest dated checkpoint after ONWARD3 reported 54% PASI 100 at 48 weeks; filing and eventual approval remain distinct hurdles [#SEC-8K-2026-08-13] [#8-K-2026-09-01].
Prob 75.00% • Move 25.00% • Priced-in 45.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

A-005 Parkinson’s biomarker trial initiation
2027-06-30
Alumis planned to initiate a Phase 2 biomarker trial of its CNS-penetrant TYK2 inhibitor A-005 in the first half of 2027. Initiation would advance the program, but it is not an efficacy readout [#SEC-8K-2026-08-13].
Prob 60% • Move 10% • Priced-in 10%
Regulatory path for biomarker-defined SLE development
2027-09-25
Following the LUMUS failure on primary and secondary endpoints in the overall population, Alumis plans regulatory discussions about Phase 3 development based on a prespecified IFNGS-high subgroup. The subgroup signal preserves optionality but does not establish a viable registration path; no meeting date was supplied [#PR-EARNINGS-2026-09-01].
Prob 35% • Move 30% • Priced-in 10%

Risks

Clinical development and potential launch preparation could increase cash needs; the $502.3 million cash and marketable-securities figure is dated June 30, 2026 [#SEC-8K-2026-08-13].
LUMUS missed its primary and secondary endpoints in the overall SLE population; a prespecified subgroup response does not reverse that result [#PR-EARNINGS-2026-09-01].
Low coverage and unavailable verified current analyst-target revisions limit valuation confidence.
Regulators may not accept the proposed biomarker-defined SLE development path or the planned psoriasis NDA; submission is not approval [#8-K-2026-09-01].

Peers

Symbol	Summary
ARQT	Dermatology-focused commercial comparator identified in the prior baseline; useful for framing a potential psoriasis launch, but its commercial-stage profile is not a clean clinical-risk valuation match.
CGEM	Similar market capitalization in the supplied peer set, but indication and program differences make it only a loose biotechnology valuation comparator.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-25

Loading AI feed…

Symbol

Summary

ARQT

Dermatology-focused commercial comparator identified in the prior baseline; useful for framing a potential psoriasis launch, but its commercial-stage profile is not a clean clinical-risk valuation match.

CGEM

Similar market capitalization in the supplied peer set, but indication and program differences make it only a loose biotechnology valuation comparator.